^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Skin Cancer
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    08/07/2020
    Excerpt:
    Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    06/25/2020
    Excerpt:
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated...for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC)…
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    07/14/2020
    Excerpt:
    Squamous Cell Skin Cancer: Preferred regimens...Regional Recurrence or Distant Metastatic Disease...Cemiplimab-rwlc